Lexicon Pharmaceuticals Q3 2026 net loss widens 9% to $14 million

Bitget2026/11/05 12:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lexicon Pharmaceuticals’ third-quarter 2026 net loss widened 9% year over year to $14 million.
Total revenues fell 20% year over year to $11.3 million, including $10 million in Novo development milestone revenue.
Research and development expenses declined 14% year over year to $16.2 million, reflecting lower external research expenses.
The Phase 3 SONATA-HCM trial completed enrollment with 542 patients; top-line results are expected in the first quarter of 2027.
A ZYNQUISTA NDA resubmission is anticipated in the first quarter of 2027, supported by positive STENO1 safety data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062822-26-000124), on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lexicon Pharmaceuticals Q3 2026 net loss widens 9% to $14 million

You may also like

Crypto prices